Irinotecan is an analogue of camptothecin, a topoisomerase I inhibitor, that has an important role in the management of advanced colorectal cancer. It is approved as first-line therapy in combination with 5-fluorouracil and leucovorin or as monotherapy in the second-line setting. Its clinical use has been associated with variability in terms of pharmacokinetic behavior and toxicities, especially myelosuppression and diarrhea. Irinotecan is metabolized to the active compound SN-38; it is now known that the metabolism of irinotecan and the inactivation of SN-38 by glucuronidation are mediated by genetic differences, which contributes to the variability. In this article, a case is presented that illustrates this, and there is a brief discussion of the clinical pharmacology of irinotecan and some of the genetic variations that affect its cellular metabolism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3816/ccc.2005.n.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oxyresveratrol Alleviates Irinotecan-Induced Diarrhea and Enhances Antitumor Effects in Colorectal Cancer.
Drug Des Devel Ther
January 2025
West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Article Synopsis
- The study explored if oxyresveratrol (OXY) can reduce the intestinal side effects of irinotecan (CPT-11) and improve its effectiveness against colorectal cancer.
- OXY and CPT-11 were tested separately and together on colorectal cancer cell lines and in a mouse model, revealing that their combination enhances tumor cell growth inhibition while also alleviating CPT-11's adverse effects like diarrhea and weight loss.
- The findings suggest that using OXY with CPT-11 could be a promising approach for colorectal cancer treatment by targeting specific biological pathways.
Rifaximin alleviates irinotecan-induced diarrhea in mice model.
Ann Med
December 2024
Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Background: Irinotecan is a chemotherapeutic drug widely used to treat solid tumors. However, its effectiveness is limited by the severely delayed onset of diarrhea. This study aimed to confirm the protective effects of the non-systemic oral antibiotic rifaximin on irinotecan-induced mucositis in mice model.
View Article and Find Full Text PDFEfficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial.
Chin Med
November 2024
Department of Medical Oncology, Integrated Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, No.2, East Street, Ying Hua Yuan, Chao Yang District, Beijing, China.
Background: Irinotecan is a standard chemotherapeutic agent in small cell lung cancer (SCLC), however, as a common adverse reaction, diarrhea limits the use of irinotecan. Shengjiang Xiexin decoction (SXD) has been used in various gastrointestinal diseases in China two thousand years ago. We designed this clinical trial to supply more evidences on the use of SXD as prophylaxis for irinotecan-induced diarrhea, especially for high-risk population predicted by gene testing of uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1).
View Article and Find Full Text PDFDiscovery of the FXR/CES2 dual modulator LE-77 for the treatment of irinotecan-induced delayed diarrhea.
Bioorg Chem
December 2024
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Key Laboratory of New Drug Discovery and Evaluation of the Guangdong Provincial Education Department, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Guangzhou Key Laboratory of Construction and Application of New Drug Screening Model Systems, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Guangzhou, 510006, PR China. Electronic address:
Article Synopsis
- Irinotecan (CPT-11) is a drug used to treat colorectal cancer, but its effectiveness is limited by severe delayed diarrhea from toxic metabolites.
- The standard treatment for this diarrhea, loperamide, has its own side effects and often fails, indicating a need for better solutions.
- This study introduces LE-77, a compound that activates the Farnesoid X receptor (FXR) and inhibits the enzyme carboxylesterase 2 (CES2), successfully reducing intestinal toxicity and alleviating delayed diarrhea caused by CPT-11.
Correction: Fecal SN-38 Content as a Surrogate Predictor of Intestinal SN-38 Exposure and Associated Irinotecan-induced Severe Delayed-Onset Diarrhea by a Novel Use of the Spectrofluorimetric Method.
Pharm Res
October 2024
Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, 4349 Martin Luther King Blvd, Houston, TX, 77204, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!